
OPKO Health (OPK) Stock Forecast & Price Target
OPKO Health (OPK) Analyst Ratings
Bulls say
OPKO Health Inc. is strategically positioning itself by focusing on its drug development capabilities, resulting in a stronger balance sheet and a potentially profitable remaining lab business following recent divestitures. The company demonstrated financial resilience with a total revenue of $183.6 million in 4Q24, indicating a 0.9% year-over-year growth, surpassing projections and showcasing improved operational efficiencies. Additionally, net income was reported at $14.0 million, attributed largely to a significant realized gain from the sale of shares, suggesting a favorable trajectory for future profitability and operational performance.
Bears say
OPKO Health Inc. has reported a significant decline in revenue across its operations, with Diagnostics services revenue dropping 17% year-over-year to $103.1 million, primarily attributed to reduced clinical test volumes following asset sales. The total revenue for full-year 2024 has also decreased by 17% year-over-year to $713.1 million, compounded by a 13% decline in pharmaceutical products revenue due to unfavorable foreign currency exchange fluctuations. Additionally, persistent risks such as lower-than-projected growth in diagnostics services, challenges in regulatory approvals for new pharmaceuticals, and competition could hinder future financial performance.
This aggregate rating is based on analysts' research of OPKO Health and is not a guaranteed prediction by Public.com or investment advice.
OPKO Health (OPK) Analyst Forecast & Price Prediction
Start investing in OPKO Health (OPK)
Order type
Buy in
Order amount
Est. shares
0 shares